Blood group antigen a and flow cytometric analysis in resected early-stage non-small cell lung cancer

被引:0
|
作者
Graziano, SL
Tatum, AH
Gonchoroff, NJ
Newman, NB
Kohman, LJ
机构
[1] VET AFFAIRS MED CTR,DEPT PATHOL,SYRACUSE,NY 13210
[2] VET AFFAIRS MED CTR,DEPT SURG,SYRACUSE,NY 13210
[3] SUNY HLTH SCI CTR,SYRACUSE,NY 13210
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The loss of blood group antigen A on tumor tissue has been reported to be a strong adverse prognostic marker for patients with resected non-small cell lung cancer (NSCLC), Results have varied with respect to the prognostic significance of flow cytometric data, We sought to confirm the prognostic significance of blood group antigen A loss and flow cytometry in a large cohort of patients with early-stage NSCLC. Two hundred and sixty patients with surgically resected stage I(n = 193) and II (rt = 67) NSCLC with at least a 5-year follow-up were identified, Using paraffin-embedded primary tumor, immunohistochemical stains for blood group antigen A were performed on 90 patients with blood type A or AB, The DNA index and percentage of cells in S phase were successfully obtained on 188 and 152 patients, respectively, The median survival time of the patients with primary tumors negative for blood group antigen A was 38 months (II = 36), compared with 98 months (n = 54) for those with antigen A-positive tumors (P < 0.01), The median disease-free survival times for antigen A-negative and -positive tumors were 26 months and 98 months, respectively (P < 0.01), The median survival time of the patients with aneuploid tumors was 51 months (n = 131), compared with 50 months (n = 57) for those with diploid tumors (P = 0.42), The median survival time of the patients with S phase >8% was 44 months (n = 105), compared with 60 months (n = 47) for those with S phase less than or equal to 8% (P = 0.18), Multivariate analysis showed that the loss of antigen A, higher N and T stages, and the presence of mucin predicted for poorer disease-free and overall survival, In the subgroup of patients with blood group A or AB, the loss of antigen was the most powerful negative predictor of survival, Aneuploidy and percentage of cells in S phase were not of prognostic significance in this group of patients with resected stage I and II NSCLC. The value of blood group antigen A analysis needs to be evaluated in larger and prospective studies of early-stage NSCLC, Alteration of blood group antigen cell surface expression may represent an important marker for more aggressive biological and metastatic behavior in NSCLC.
引用
收藏
页码:87 / 93
页数:7
相关论文
共 50 条
  • [21] Time trends and predictors of survival in surgically resected early-stage non-small cell lung cancer patients
    Shewale, Jitesh B.
    Corsini, Erin M.
    Correa, Arlene M.
    Brown, Eric L.
    Leon-Novelo, Luis G.
    Nyitray, Alan G.
    Antonoff, Mara B.
    Hofstetter, Wayne L.
    Mehran, Reza J.
    Rice, David C.
    Roth, Jack
    Walsh, Garrett L.
    Vaporciyan, Ara A.
    Swisher, Stephen G.
    Sepesi, Boris
    JOURNAL OF SURGICAL ONCOLOGY, 2020, 122 (03) : 495 - 505
  • [22] Treatment Patterns and Outcomes in Resected Early-stage Non-small Cell Lung Cancer: An Analysis of the SEER-Medicare Data
    West, Howard
    Hu, Xiaohan
    Zhang, Su
    Song, Yan
    Chirovsky, Diana
    Gao, Chi
    Lerner, Ariel
    Jiang, Anya
    Signorovitch, James
    Samkari, Ayman
    CLINICAL LUNG CANCER, 2023, 24 (03) : 260 - 268
  • [23] Lack of Prognostic Significance of Neuroendocrine Differentiation and Stem Cell Antigen Co-Expression in Resected Early-stage Non-small Cell Lung Cancer
    Gottschling, Sandra
    Jensen, Katrin
    Herth, Felix J. F.
    Thomas, Michael
    Schnabel, Philipp A.
    Herpel, Esther
    ANTICANCER RESEARCH, 2013, 33 (03) : 981 - 990
  • [24] Comprehensive sampling of the lung microbiome in early-stage non-small cell lung cancer
    Reddy, Rishindra M.
    Lagisetty, Kiran
    Lin, Jules
    Chang, Andrew C.
    Achreja, Abhinav
    Ramnath, Nithya
    Nagrath, Deepak
    Dickson, Robert
    Weinberg, Frank
    JTCVS OPEN, 2024, 17 : 260 - 268
  • [25] Immune checkpoint inhibition in early-stage non-small cell lung cancer
    Cuppens, Kristof
    Du Pont, Bert
    Knegjens, Joost
    Maes, Brigitte
    Baas, Paul
    LUNG CANCER, 2024, 193
  • [26] Nonintubated thoracoscopic surgery for early-stage non-small cell lung cancer
    Wan-Ting Hung
    Ya-Jung Cheng
    Jin-Shing Chen
    General Thoracic and Cardiovascular Surgery, 2020, 68 : 733 - 739
  • [27] Evaluation of outcome by race in early-stage non-small cell lung cancer
    Jahanzeb, M
    Virgo, KS
    McKirgan, LW
    Johnson, FE
    ONCOLOGY REPORTS, 1997, 4 (01) : 183 - 186
  • [28] Features of fatigue in patients with early-stage non-small cell lung cancer
    Huang, Xianping
    Zhou, Weihe
    Zhang, Yuefeng
    JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2015, 20 (03): : 268 - 272
  • [29] Health behaviors of early-stage non-small cell lung cancer survivors
    Paul Krebs
    Elliot J. Coups
    Marc B. Feinstein
    Jack E. Burkhalter
    Richard M. Steingart
    Amy Logue
    Bernard J. Park
    Jamie S. Ostroff
    Journal of Cancer Survivorship, 2012, 6 : 37 - 44
  • [30] Immunotherapy for early-stage non-small cell lung cancer: A system review
    Gao, Jingyi
    Zhang, Chao
    Wei, Zhigang
    Ye, Xin
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (04) : 849 - 865